JAY Chemical Industries Private Limited Overview
JAY Chemical Industries is India's largest and one of the world's top five producers of reactive dyes, the colourants used on cotton and other cellulosic textiles. It is a family-controlled, unlisted company founded in Ahmedabad in 1967. CARE Ratings estimates its share of the domestic reactive-dye market at about 25% and its share of India's reactive-dye exports at about 14%. Its core advantage is backward integration. In-house production of vinyl sulphone (8,400 MTPA) and H-acid (4,800 MTPA) covers more than 90% of its needs for these two key intermediates. This lets JCIPL sustain EBITDA margins near 15%, well above listed Indian dye peers. Its main plant at Khambhat runs on zero liquid discharge, a growing advantage as pollution rules tighten in India and China. JCIPL is now diversifying from a reactive-dye base (87% of revenue in 9MFY2025) into disperse dyes, surfactants and specialty chemicals at Saykha. It is also building direct export channels in Turkey, Vietnam and Bangladesh.
What the company does
JCIPL makes synthetic dyestuffs and textile chemicals for the wet-processing (dyeing, printing and finishing) stage of the textile value chain. Revenue is dominated by reactive dyes. These bond chemically with cellulose fibres (cotton, viscose, linen) and are used for exhaust, semi-continuous, continuous and printing processes. CARE describes a portfolio of more than 200 dye and dye-intermediate varieties. JCIPL also manufactures the main intermediates for those dyes: vinyl sulphone (VS), H-acid and copper phthalocyanine crude (CPC). Adjacent product lines include:
-
disperse dyes for polyester (Jaylene);
-
acid dyes for nylon, silk and some leather (Nilan);
-
textile auxiliaries for pre-treatment, dyeing and finishing (OXXI.J);
-
surfactants and ethylene oxide/propylene oxide (EO/PO) derivatives (Surten);
-
water-treatment chemicals (Akwakare).
Related group entities make digital textile printing inks (Antelos, via Solunaris) and construction chemicals (K2, via Konkem Industries).
Company's own description
The website presents JCIPL as one of the world's top reactive-dye producers, with presence in over 40 countries and annual revenue above USD 200 million. It says the company accounts for more than 15% of India's reactive-dye production. Its stated vision is to become the "best and the biggest reactive dyestuff producer in the world." The company also highlights backward integration covering over 50% of its raw-material needs, as an outcome of a deliberate self-reliance strategy. No annual report narrative is public.
Independent characterisation
JCIPL is a mid-sized, integrated specialty-colourant manufacturer. Its economics are mixed:
Commodity exposure: Raw materials are petroleum- and sulphur-based and imported in part. Textile demand is cyclical.
Specialty traits: Customer-specific shade matching, brand-level compliance certifications (ZDHC, bluesign, Inditex "The List", ECO PASSPORT, GOTS) and technical service through its NABL-accredited "Vortex" laboratory support pricing.
Its margin premium over listed Indian peers comes mainly from two sources: captive intermediates and a high-compliance, zero-liquid-discharge (ZLD) asset base. Since roughly FY2022 it has been in an investment phase. CARE notes that heavy capex on compliance and diversification has held return on capital employed (ROCE) near 10%.
Business and revenue model
| Dimension | Characterisation |
|---|---|
| Revenue model | ~100% product sales. No subscription or licensing revenue is disclosed. Technical service is bundled into product sales. |
| Product vs service | Product. Application support from the Vortex lab is a sales enabler, not a separate revenue line. |
| Value chain position | Mid-stream. It buys benzene/naphthalene-derived and sulphur-based raw materials, makes intermediates (VS, H-acid, CPC), converts them to finished dyes, and sells to textile processors (dye houses, mills, garment-processing units). |
| Go-to-market (India) | Agent network across dye-consuming centres, plus direct sales to major customers. Warehousing near textile hubs aims at sub-24-hour delivery (company plan, 2015). Over 4,000 domestic customers (Sep-2024). |
| Go-to-market (export) | Agency network plus overseas marketing subsidiaries in Turkey, Vietnam, Bangladesh and Germany. Warehouses in Turkey and Vietnam; direct selling in Bangladesh began in FY2025. |
| Customer types | Textile dye houses and process houses; vertically integrated mills; garment exporters; digital-print OEMs (inks); leather tanneries (acid dyes); construction trade (K2, group company) |
| End markets | Textiles (~80% of global dye consumption, per CARE) in apparel, home textiles and denim-adjacent cotton processing; leather; paper and other minor uses |
| Customer concentration | Low. CARE notes no major dependence on any single customer. |
Strategy
Stated strategic themes (company materials)
-
Leadership in reactive dyes. The stated vision is to become the best and biggest reactive-dyestuff producer in the world.
-
Self-reliance and backward integration. Integration covers over 50% of raw-material needs, and VS and H-acid capacity meets more than 90% of those intermediates.
-
R&D intensity. The company says about 4% of annual earnings is reserved for R&D, with a pilot plant bridging the lab and commercial production.
-
Sustainability. About 3% of revenue is earmarked for sustainability and social programmes. The company cites ZLD, 100% recycled water, 55% renewable energy, and products that cut customers' water, energy and salt use.
-
Total solution provider. The aim is to cover the textile wet-processing chain from sizing to finishing with reactive, disperse and acid dyes plus auxiliaries.
-
Customer service and consistency as the main differentiator.
Initiatives in the last 24 months and the recent investment cycle
| Initiative | Timing | Description | Status |
|---|---|---|---|
| Disperse dye platform (Jaylene, Saykha) | Project Oct-2021; inaugurated Jun-2023 | 12,000 MTPA; targets polyester growth in sports and activewear | Ramp-up; 21% utilisation in 9MFY2025 |
| Specialty chemicals / surfactants (Surten, Saykha) | Inaugurated 28-Jun-2024 | EO/PO derivatives and formulated products; backward integration into auxiliaries plus home and personal care | Commercial operations FY2025; <1% of revenue |
| Water-treatment chemicals (Akwakare) | Announced 2024 | New specialty vertical | Early stage |
| Overseas distribution transformation | FY2025 | Warehouses in Türkiye and Vietnam; direct selling in Bangladesh; more overseas warehouses planned | Delivered 47% export-volume growth in 9MFY2025 |
| Renewable energy | Through Dec-2024 | 14.3 MW solar and 6.2 MW wind | Operating |
| Balance-sheet discipline | FY2025–FY2026 | No major capex planned for FY2026; term loan reduced | Ongoing |
Medium-term targets and guidance
The company publishes no formal financial guidance. CARE's stated rating sensitivities act as implicit external benchmarks:
Upside: TOI above ₹2,000 crore with EBITDA margin above 14% sustained, and ROCE of about 15%.
Downside: EBITDA margin below 11%, or total debt/GCA above 3x.
CARE's own projections are about ₹1,600 crore of TOI in FY2025 at about 15% EBITDA margin, ROCE of 10–12% over the medium term, and about ₹200 crore of cash accruals in FY2026.
Products & Services
Reactive dyes (core; ~87% of revenue)
| Brand / line | Description | Key capabilities | Target customer | Launch | Pricing |
|---|---|---|---|---|---|
| JAKAZOL® | Reactive dyes for cellulosic fibres. Spelled "Jakozol" in CARE and some directories; the company uses "JAKAZOL". | Suitable for exhaust, semi-continuous, continuous and printing processes. Offered for cost-focused, mid-market and high-performance tiers. | Cotton and viscose dye houses, knit and woven processors | Long-standing (year n/d) | — |
| JAKOFIX® | Reactive dyes, high-performance range | High "right-first-time" performance under varying process conditions (time, temperature, liquor ratio). Low-salt variants reduce effluent dissolved solids. Reduced-wash and lower-temperature washing variants. | Premium processors supplying global apparel brands | Long-standing (year n/d) | — |
| Tailor-made reactive dyes | Custom shades and formulations | Customer-specific development through the Vortex lab | Large mills and brand-nominated suppliers | Ongoing | Contract |
Capacity: 55,200 MTPA reactive dyes at 31-Dec-2024 (CARE). The Sep-2024 trade article cites 55,000 MTPA.
Disperse dyes
| Brand | Description | Capabilities | Target | Launch |
|---|---|---|---|---|
| JAYLENE® | Disperse dyes for polyester and blends | Aimed at fashion, sports and activewear polyester. Positioned with Jakazol/Jakofix for cellulosic–polyester blends. | Synthetic and blend processors | Small-scale production c. 2013. Dedicated Saykha plant inaugurated 1-Jun-2023. |
Capacity: 12,000 MTPA. CARE's text describes this both as "disperse dyes" capacity and as "disperse dyes intermediates" capacity; the Sep-2024 trade article cites 12,000 MTPA combined for disperse and acid dyes. Utilisation was 21% in 9MFY2025 (CARE).
Acid dyes
| Brand | Description | Target | Launch |
|---|---|---|---|
| NILAN | Acid dyes for nylon, silk and some leather applications | Polyamide and silk processors, tanneries | n/d (active by 2024) |
Textile auxiliaries
| Brand | Description | Target | Capacity |
|---|---|---|---|
| OXXI.J | Textile chemicals covering the full wet-processing chain from sizing and pre-treatment through dyeing to finishing | Process houses wanting a single supplier | 24,000 MTPA textile chemicals (trade article, Sep-2024) |
Specialty chemicals and surfactants
| Brand | Description | Target | Capacity / start |
|---|---|---|---|
| SURTEN | EO/PO-based derivatives and formulated surfactants that lower surface and interfacial tension. Used as feedstock for auxiliaries and sold for home care and personal care applications. | Auxiliary formulators, home-care and personal-care manufacturers, water treatment | Saykha plant inaugurated 28-Jun-2024. CARE cites 6,000 MTPA; the trade article cites 25,000 MTPA for Surten specialty chemicals. The discrepancy may reflect phase versus planned capacity. |
Water-treatment chemicals
| Brand | Description | Status |
|---|---|---|
| AKWAKARE (with SURTEN) | Water-treatment chemical range | Early-stage expansion announced in 2024 |
Dye intermediates (mainly captive)
| Product | Use | Capacity, 31-Dec-2024 (MTPA) |
|---|---|---|
| Vinyl sulphone (VS) | Key reactive-dye building block | 8,400 |
| H-acid | Key intermediate for black and navy reactive dyes | 4,800 |
| Copper phthalocyanine crude (CPC) | Turquoise reactive dyes; pigments | 3,600 |
VS and H-acid capacity covers more than 90% of JCIPL's own requirement for these two intermediates. The company decides case by case whether to make or buy, depending on market prices (CARE).
Legacy and other dye classes
Trade-portal listings (fibre2fashion, undated) also show vat dyes and direct dyes. Their current commercial weight is n/d. Direct Blue dyes were the founding product in 1967.
Group offerings (outside JCIPL)
| Brand | Entity | Description |
|---|---|---|
| ANTELOS® | Solunaris (India / Germany) | Digital textile printing inks for natural and synthetic fibres. Covers major current print-head technologies. Sold as OEM supply to some digital-printer makers and in the replacement-ink market. |
| K2 | Konkem Industries | Construction chemicals: waterproofing, grouts, plasticisers, tile adhesives, joint fillers, epoxy bonding agents. Tagline "Restructuring Konstruction. Kemically." |
Compliance attributes (cross-portfolio)
Certifications: ISO 9001:2015, ISO 14001:2015, ISO 45001:2018.
Product compliance: ZDHC contributor; ECO PASSPORT; Inditex "The List"; GOTS; bluesign; ETAD member; Oeko-Tex 100 (cited 2015).
Laboratory: NABL-accredited.
Financial Narrative
Coverage limitation. Only FY2023 (audited), FY2024 (audited) and 9MFY2025 (unaudited) consolidated figures are public, via CARE Ratings (10-Mar-2025). These are reclassified to CARE standards. FY2021, FY2022, FY2025 actual and FY2026 actual figures are not publicly disclosed. Statutory accounts are on file with the MCA but were not accessed. Gross profit, EPS, dividends per share, cash, buybacks, goodwill and capex are not publicly disclosed.
Income statement (consolidated, INR crore)
Source: CARE Ratings PR, 10-Mar-2025, "Brief Financials" and text. Margins and implied interest are derived (interest = PBILDT ÷ coverage).
Source: CARE, Mar-2025. FY2024 growth is derived from TOI.
Long-run revenue trajectory (INR crore)
Sources: Textile Magazine (Jul-2015) for FY2005 and FY2015; CARE (Mar-2025) for FY2023, FY2024 and the FY2025E projection of 15–16% growth to about ₹1,600 crore.
Revenue CAGR (derived):
-
FY2005–FY2015: about 25.9%.
-
FY2015–FY2024: about 3.8% (lower bound, since FY2015 was "over" ₹1,000 crore).
-
FY2023–FY2025E: about 2.9%.
The pattern is hyper-growth up to 2015, then a long plateau through the 2016–2024 textile and raw-material cycles.
Balance sheet and leverage (INR crore)
Derivation: FY2023 debt = 1.34 × PBILDT; FY2024 debt = 1.30 × PBILDT; Dec-2024 debt = 0.22 × net worth; FY2023 net worth = debt ÷ 0.30. The FY2024 cross-check (0.25 × 1,073 = 268) agrees within 1%.
The rising depreciation proxy (+32% YoY) is consistent with the Saykha disperse plant (Jun-2023) entering the asset base.
Debt structure (Mar-2025 rated facilities):
-
Long-term term loan: ₹113.17 crore, maturing 16-Aug-2027.
-
Fund-based LT/ST working capital: ₹365 crore.
-
Export credit (EPC/PSC): ₹130 crore.
-
Non-fund-based facilities: ₹60 crore.
-
Total rated: ₹668.17 crore.
The short- and long-term split of drawn debt, cash and equivalents, net debt, goodwill and intangibles, and working capital in rupees are not publicly disclosed. CARE reports average fund-based working-capital utilisation of about 60% over the 12 months to Dec-2024.
Ratios
Not publicly disclosed: ROA, ROIC on a reported basis, current ratio, asset turnover, cash conversion cycle and net debt/EBITDA (cash n/d). CARE describes the fixed-asset turnover ratio as "moderate", owing to non-revenue-generating compliance capex.
Commentary on trends and drivers
Margin resilience: Revenue fell 7.6% in FY2024, yet EBITDA margin rose 40 bps to 14.91%. In 9MFY2025 it widened further to 15.75% on 26% volume growth and better operating leverage. This is the clearest evidence that backward integration cushions intermediate-price volatility. Listed peer Bodal Chemicals earned a 9.7% consolidated EBITDA margin in FY2025.
Return dilution: ROCE of about 10% (FY2024) is well below what the margin profile would suggest. Capital employed has grown faster than earnings: net worth rose about 19% from FY2023 to Dec-2024, while trailing EBITDA was broadly flat. CARE's upgrade trigger requires sustained ROCE of about 15%, plus TOI above ₹2,000 crore and EBITDA margin above 14%.
Inflection in FY2025: Export-led volume recovery (+47% in export volume in 9MFY2025) followed the switch to owned warehouses and direct selling. This reverses the FY2024 slowdown, which was driven by lower realisations.
Deleveraging: Gearing fell from 0.30x to 0.22x in about 21 months, and the term loan was cut from ₹200 crore to ₹113 crore of rated amount. The balance sheet has meaningful headroom for the next investment cycle.
Disclosure gap: FY2025 audited and FY2026 figures should exist in MCA filings and in a CARE surveillance review expected around Feb–Mar 2026. Neither was located in public sources at the dossier date. Analysts should obtain them before any credit or valuation decision.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Product Lines
| Product line (9MFY2025) | Share of revenue (%) | Implied revenue, 9MFY2025 (INR Cr, derived) | Contents |
|---|---|---|---|
Reactive dyes | 87.0 | 1,072.7 | Jakazol, Jakofix and tailor-made reactive dyes for cellulosics |
Disperse dyes | 3.5 | 43.2 | Jaylene range for polyester (Saykha) |
Surfactants | <1 | <12.3 | Surten EO/PO derivatives (Saykha; commercial operations in FY2025) |
Auxiliary chemicals and other (balance) | ~8.5–9.5 | ~105–117 | OXXI.J textile auxiliaries, intermediates sold externally, acid dyes (Nilan), water-treatment chemicals |
Total TOI | 100 | 1232.95 | — |
Group Entities
| Entity | Country | Relationship | Consolidation | Function |
|---|---|---|---|---|
JAY Chemical Industries Pvt. Ltd. | India | Parent | Full | Manufacturing, domestic and export sales |
Solunaris GmbH | Germany | Subsidiary | Full | Digital textile printing inks (Antelos) |
Jay Boya Kimya Limited Şirketi | Türkiye | Subsidiary | Full | Overseas marketing and warehousing |
Jay Chemical Vietnam Company Limited | Vietnam | Subsidiary | Full | Overseas marketing and warehousing |
Jay Chemical Bangladesh Private Limited | Bangladesh | Subsidiary | Full | Overseas marketing and direct selling |
Khambhat Environ Care Association | India | Associate | Moderate | Shared environmental infrastructure (waste treatment, landfill) |
Group Entities — Solunaris Private Limited
| Entity | Business | Notes |
|---|---|---|
Solunaris Private Limited (India) | Digital textile printing inks (Antelos) | Listed as a group company on JCIPL's website |
Konkem Industries Private Limited | Construction chemicals, brand "K2" | Plant at Sanand, Gujarat. Products include waterproofing compounds, grouts, plasticisers, tile adhesives, joint fillers and epoxy bonding agents. |
Jay Infa Trade Private Limited | Not disclosed (trading-class CIN) | A JCIPL director has held a directorship since 1-Nov-2005 (MCA via ZaubaCorp) |
Garment manufacturing activity | Garments | Mentioned in company descriptions; entity not identified |
Income Statement and Margin Analysis (%)
| Metric | FY2023 | FY2024 | 9MFY2025 |
|---|---|---|---|
Total operating income (INR Cr) | 1,510.68 | 1,396.62 | 1,232.95 |
PBILDT / EBITDA (INR Cr) | 219.14 | 208.22 | 194.25 |
PAT (INR Cr) | 103.75 | 86.92 | 89.24 |
EBITDA margin (%) | 14.51 | 14.91 | 15.75 |
PAT margin (%, derived) | 6.87 | 6.22 | 7.24 |
Interest coverage, PBILDT/interest (x) | 11.80 | 9.37 | 13.03 |
Implied interest expense (INR Cr, derived) | 18.57 | 22.22 | 14.91 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2024 | 9MFY2025 |
|---|---|---|
TOI growth YoY (%) | -7.55 | 25.0 |
Sales volume growth YoY (%) | — | 26.0 |
Export volume growth YoY (%) | — | 47.0 |
Domestic volume growth YoY (%) | — | 7.0 |
Financial Analysis
| Metric | FY2005 | FY2015 | FY2023 | FY2024 | FY2025E |
|---|---|---|---|---|---|
Revenue (INR Cr; FY2015 = "over 1000"; FY2025 = CARE projection) | 100 | 1,000 | 1,510.68 | 1,396.62 | 1,600 |
Key Financials and Financial Ratios (x)
| Metric | FY2023 | FY2024 | Dec2024 |
|---|---|---|---|
Net worth (INR Cr; FY2023 derived) | 978.7 | 1,073 | 1,167 |
Overall gearing (x) | 0.30 | 0.25 | 0.22 |
Total debt (INR Cr, derived) | 293.6 | 270.7 | 256.7 |
Financial Ratios (x)
| Metric | FY2024 | Dec2024 |
|---|---|---|
TOL/TNW (x) | 0.58 | 0.62 |
Financial Ratios (x) and Income Statement
| Metric | FY2023 | FY2024 |
|---|---|---|
Total debt/PBILDT (x) | 1.34 | 1.30 |
Total debt/GCA (x) | 1.80 | 1.64 |
Gross cash accruals (INR Cr, derived) | 163.1 | 165.1 |
Implied depreciation and non-cash items (INR Cr, derived = GCA − PAT) | 59.4 | 78.2 |
Financial Analysis — Capex
| Item | Status |
|---|---|
Capex | n/d in amount. Qualitatively large over FY2022–FY2025 (Saykha disperse plant, Saykha specialty chemicals plant, compliance capex, 14.3 MW solar and 6.2 MW wind). CARE expects no major capex in FY2026. |
Expected cash accruals, FY2026 | ~₹200 crore (CARE projection) against scheduled debt repayment of ~₹44 crore |
Dividends paid / buybacks | n/d (private company) |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2023 | FY2024 |
|---|---|---|
ROE on closing equity (%, derived) | 10.60 | 8.10 |
ROCE (%, CARE) | — | 10.0 |
Operating ROCE (%, CARE) | — | 11.5 |
Debt/equity (x) | 0.30 | 0.25 |
Total debt/EBITDA (x) | 1.34 | 1.30 |
Interest coverage (x) | 11.80 | 9.37 |
Revenue by Region (%)
| Metric | FY2015 | FY2024 | 9MFY2025 |
|---|---|---|---|
Domestic share of revenue (%) | 40 | 54 | 49 |
Export share of revenue (%) | 60 | 46 | 51 |
Revenue by Region
| Metric | FY2024 | 9MFY2025 |
|---|---|---|
Domestic revenue (INR Cr, derived) | 754.2 | 604.1 |
Export revenue (INR Cr, derived) | 642.4 | 628.8 |
Network Type Details
| Network type | Countries |
|---|---|
Agency network | Argentina, Austria, Bangladesh, Brazil, Egypt, Germany, Greece, Guatemala, Italy, Mexico, Pakistan, Peru, Portugal, Sri Lanka, Switzerland, Türkiye, U.K., USA |
Sales presence | China, Colombia, Dominican Republic, Ecuador, Ethiopia, Hong Kong, Indonesia, Japan, Korea, Nepal, South Africa, Singapore, Taiwan, Thailand, Tunisia, Vietnam, Australia |
Representatives | Germany, Türkiye, Italy, Singapore, U.K., Honduras |
Capital Markets
| Item | Status |
|---|---|
Share price performance (1/3/5-year) | Not applicable (unlisted) |
Valuation multiples (P/E, EV/EBITDA, EV/Sales, P/B) | Not applicable. No transaction-implied valuation disclosed. |
Analyst consensus | None (no equity coverage) |
Equity issuance / IPO plans | None announced |
Debt Facilities
| Facility | Amount (INR Cr) | Rating | Action, 10-Mar-2025 |
|---|---|---|---|
Long-term term loan (maturity 16-Aug-2027) | 113.17 | CARE A+; Stable | Reaffirmed (reduced from 200.00) |
Fund-based LT/ST | 365.00 | CARE A+; Stable / CARE A1+ | Reaffirmed |
Fund-based ST (EPC/PSC) | 130.00 | CARE A1+ | Assigned |
Non-fund-based ST | 60.00 | CARE A1+ | Reaffirmed |
Total | 668.17 | — | — |
Capital Markets (Annual)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Rated facilities, CARE long-term rating notch (A+ = 5 on an AAA = 1 scale) | 5 | 5 | 5 | 5 |
Analyst Conclusions
Guidance and consensus
Management guidance: none published.
External projection (CARE, Mar-2025): - FY2025 TOI about ₹1,600 crore (+15–16%) at about 15% EBITDA margin.
-
Medium-term ROCE 10–12%.
-
FY2026 cash accruals about ₹200 crore, with no major capex.
Consensus: none (no equity coverage).
Bull case
-
Operating leverage on idle capacity. The Saykha disperse plant (21% utilisation) and surfactant plant (under 1% of revenue) are already built and depreciating. Every point of utilisation gain falls through at high incremental margin, which could lift ROCE toward CARE's 15% trigger without new capex.
-
Export channel momentum. Export volumes grew 47% in 9MFY2025 after warehouse and direct-selling changes in Türkiye, Vietnam and Bangladesh. Garment production shifting to these hubs under China+1 and US tariff realignment could sustain double-digit export growth.
-
Compliance-led consolidation. As unorganised Indian capacity and non-compliant Chinese capacity exit, JCIPL's ZLD sites, 25% domestic share and 15%+ margins position it to take share at stable or better pricing.
Bear case
-
Structural growth deficit. Revenue compounded below 4% a year from FY2015 to FY2024. The FY2025 rebound may be cyclical restocking rather than a step change.
-
Diversification without returns. New lines contributed about 4.5% of revenue in 9MFY2025 despite multi-year capex. If utilisation stalls, ROCE stays near 10%, below a reasonable cost of capital.
-
Demand and trade shocks. About half of revenue depends on Indian textile processors, whose US-bound exports face steep tariffs from Aug-2025. Peers Kiri (FY2026 operating losses) and AksharChem (Negative outlook, Feb-2026) show how quickly sector margins can erode.
Catalysts and monitorables (next 12 months)
-
FY2025 and FY2026 audited results (MCA filings): confirm whether the ~₹1,600 crore projection and ~15% margin were achieved.
-
The next CARE surveillance release: rating action, updated product mix, capacity utilisation.
-
Disperse and surfactant utilisation, versus 21% and under 1% revenue share in 9MFY2025.
-
Export share and new overseas warehouse openings.
-
US–India trade negotiations and their effect on Indian garment and textile export volumes.
-
H-acid and VS price trends and Chinese intermediate supply.
-
Any new capex announcement that would end the FY2026 "no major capex" pause.
-
Clarity on the 2022 scheme of arrangement and any group restructuring (Konkem, Solunaris).
Analyst verdict
JAY Chemical Industries is a high-quality, under-earning franchise. On the evidence available, it is the best-run reactive-dye manufacturer in India. It holds about a quarter of the domestic market and about 14% of reactive-dye exports. It is backward-integrated into the two intermediates that drive most of the sector's cost volatility, and it runs a zero-liquid-discharge asset base, an increasingly valuable licence to operate. These traits show up in its numbers. EBITDA margins held near 15% through a revenue downturn, compared with about 10% at its closest listed peer. Leverage is negligible (0.22x gearing) and interest coverage is in double digits. CARE's A+/A1+ rating has held through four consecutive annual reviews.
The weakness is capital efficiency, not quality. Revenue has barely grown in real terms since FY2015. The disperse dye, surfactant and specialty chemical lines, built at significant cost between 2021 and 2024, still contribute under 5% of sales, which leaves ROCE near 10%. The investment case therefore rests on execution, not on new strategy. Can JCIPL fill the plants it has already built, and can the export distribution model that drove a 47% volume surge in 9MFY2025 scale to more markets?
From a credit standpoint, the profile is solid. Cash accruals of about ₹200 crore against about ₹44 crore of FY2026 repayments, with no major capex planned, imply continued deleveraging. From a strategic or equity standpoint, relevant to any future capital raise or partnership, the company's opacity is the main discount factor. It does not publish an annual report, and its own revenue claims diverge by about 30% from rating-agency figures. Users should obtain FY2025 and FY2026 MCA filings and the 2026 CARE surveillance report before relying on this profile.
Overall assessment: a strong-moat, low-return company at an inflection. The direction is positive if utilisation and export gains persist through FY2026–FY2027. The risk is skewed to textile-cycle and trade-policy shocks.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure / background |
|---|---|---|
Jayendra Hiralal Kharawala | Founder and Chairman, Director | Founded the business in 1967; four-generation dye-trading family; called one of the pioneers of reactive-dye manufacture in India (CARE) |
Greeven Jayendrabhai Kharawala | Managing Director | Joined 1996; 25+ years in the business (CARE) |
Dakshesh Mohanlal Machhar | Director | Public spokesman in 2015; involved in integration and commercial strategy |
Ravi Babulal Kabra | Director | Oversees the specialty chemicals vertical (Saykha EO/PO plant, 2024) |
Bipinchandra Rugnathbhai Patel | Director | — |
Alpesh Popatlal Shah | Director | — |
Executive Leadership Team
| Name | Title | Source |
|---|---|---|
Advait Purani | VP, Marketing | Textile Magazine, Sep-2024 |
Ritesh Shinde | Sales Manager | Apparel Resources, Jul-2024 |
Competitive Landscape
Key Competitors
| # | Competitor | HQ | Listing | Overlap with JCIPL | Positioning vs JCIPL |
|---|---|---|---|---|---|
| 1 | Bodal Chemicals Ltd | Ahmedabad, India | NSE/BSE | Reactive dyes, H-acid/VS-type intermediates, basic chemicals | Larger and more diversified into chlor-alkali; lower margins (FY2025 EBITDA 9.7%) |
| 2 | Kiri Industries Ltd | Ahmedabad, India | NSE/BSE | Reactive dyes and intermediates; minority stake in DyStar | Smaller and loss-making at the operating level in FY2026; value tied to DyStar litigation outcome |
| 3 | Atul Ltd (Colors segment) | Valsad, India | NSE/BSE | Reactive, disperse and other dyes | — |
| 4 | Colourtex Industries | Surat, India | Private | Reactive and disperse dyes | Large private peer (figures n/d) |
| 5 | AksharChem (India) Ltd | Gujarat, India | NSE/BSE | Pigments and dye intermediates (CPC-linked) | Smaller; CARE outlook revised to Negative in Feb-2026 |
| 6 | Bhageria Industries Ltd | India | NSE/BSE | Dye intermediates | Smaller, intermediates-focused |
| 7 | DyStar Global Holdings | Singapore (controlled by Zhejiang Longsheng) | Unlisted subsidiary | Full textile dye and auxiliary range | Global leader; brand and service scale |
| 8 | Archroma (incl. former Huntsman Textile Effects) | Switzerland | Private (SK Capital) | Reactive and disperse dyes, auxiliaries | Premium global player with brand-compliance strength |
| 9 | Zhejiang Longsheng Group | China | Shanghai SE | Disperse and reactive dyes, intermediates | Largest global dye producer; dominant in disperse |
| 10 | Zhejiang Runtu | China | Shenzhen SE | Reactive and disperse dyes, intermediates | Large Chinese integrated competitor |
| 11 | Everlight Chemical | Taiwan | TWSE | Reactive (Everzol) and disperse dyes | Premium Asian competitor |
| 12 | Unorganised Gujarat and Maharashtra dye makers | India | Private | Commodity reactive dyes | Price competition; weaker compliance (CARE) |
Peer Comparison FY2025
| Metric | JCIPL | Bodal Chemicals | Kiri Industries |
|---|---|---|---|
Revenue FY2025 (INR Cr; JCIPL = CARE estimate) | 1,600 | 1,756.7 | 740.0 |
Revenue FY2024 (INR Cr; Bodal derived from +24% growth) | 1,396.6 | 1,416.7 | 708.6 |
Revenue growth FY2025 (%) | 15.5 | 24.0 | 4.4 |
EBITDA margin, latest (%) | 15.75 | 9.7 | — |
PAT FY2025 (INR Cr; JCIPL = 9MFY2025) | 89.2 | 18.5 | — |
Credit rating (CARE) | A+ / A1+ | — | — |
Recent Developments
Public company-specific news for April 2025 to October 2026 is very sparse. The company issues few press releases; its website news page was last updated in May 2023; and its CARE surveillance review for 2026 was not located.
*Not found: layoffs, litigation, regulatory closure notices or leadership changes for 2025–2026. CARE noted no adverse pollution-control-board observations in the 12 months to Mar-2025.
